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In order to identify new genes with differential expression in early intestinal tumours, we performed mRNA
(messenger ribonucleic acid) expression proﬁling of 16 human and 63 mouse adenomas. All individuals
had germline APC mutations to ensure that tumorigenesis was driven by ‘second hits’ at APC. Using strin-
gent ﬁltering to identify changes consistent between humans and mice, we identiﬁed 60 genes up-regulated
and 151 down-regulated in tumours. For 22 selected genes—including known Wnt targets—expression differ-
ences were conﬁrmed by qRT–PCR (quantitative reverse transcription polymerase chain reaction). Most, but
not all, differences were also present in colorectal carcinomas. In situ analysis showed a complex picture.
Expression of up-regulated genes in adenomas was usually uniform/diffuse (e.g. ITGA6)o rp r o m i n e n ti n
the tumour core (e.g. LGR5); in normal tissue, these genes were expressed at crypt bases or the transit ampli-
fying zone. Down-regulated genes were often undetectable in adenomas, but in normal tissue were expressed
in mesenchyme (e.g. GREM1/2) or differentiated cells towards crypt tops (e.g. SGK1). In silico analysis of
TCF4-binding motifs showed that some of our genes were probably direct Wnt targets. Previous studies,
mostly focused on human tumours, showed partial overlap with our ‘expression signature’, but 37 genes
were unique to our study, including TACSTD2, SEMA3F, HOXA9 and IER3 (up-regulated), and TAGLN,
GREM1, GREM2, MAB21L2 and RARRES2 (down-regulated). Combined analysis of our and published
human data identiﬁed additional genes differentially expressed in adenomas, including decreased BMPs
(bone morphogenetic proteins) and increased BUB1/BUB1B. Several of the newly identiﬁed, differentially
expressed genes represent potential diagnostic or therapeutic targets for intestinal tumours.
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To the limit of its current resolution, genetic evidence suggests
that most early colorectal adenomas in humans, and intestinal
adenomas in the equivalent mouse models, have developed
solely as a result of bi-allelic inactivation of the APC gene.
Gene expression changes in these early tumours can therefore
be taken as candidate Wnt signalling targets, being driven
directly or indirectly by the increase in beta-catenin-mediated
signalling that loss of APC function causes.
The normal intestinal crypt is subject to a gradient of extrinsic
Wntsignalling,withamaximumatthecryptbasewherethestem
cells almost certainly reside, and a minimum at the top of the
crypt or villus where fully differentiated cells are shed into the
gut lumen. Three categories of putative Wnt target gene have
been suggested (1). The ﬁrst type of gene is expressed primarily
intheproliferatingortransitamplifyingcellsofthenormalcrypt,
and includes established Wnt targets such as MYC. The second
type of gene—e.g. MMP7 and the cryptdins—is a marker of
Paneth cell differentiation in the small bowel. The third type of
gene principally shows expression in the bases of normal intesti-
nal crypts, perhaps in the crypt stem cells. There are probably
several reasons for these differences in expression patterns,
including the actions of other signalling pathways such as the
Eph/Efn, Bmp and Delta/Notch systems. Although colorectal
tumours generally show over-expression of Wnt targets, it is
not clear whether their molecular phenotypes most closely
resemble normal cells with type 1, 2 or 3 gene expression.
Understanding the full transcriptional programme of Wnt sig-
nalling andits downstream effects isimportant.Proven transcrip-
tional Wnt targets include MYC, CCND1, CD44 and AXIN2.
Genes with reduced levels of expression may also be found in
regions of high physiological Wnt signalling or in colorectal
tumours. Many of these down-regulated transcripts are likely to
be genes involved in the functioning of differentiated cells.
Examples include genes/proteins involved in the absorption of
nutrients (e.g. lipoprotein lipases and alkaline phosphatases) or
in instructing cell differentiation (e.g. HATH1 that is involved
in cell fate direction towards the secretory lineage).
There has been a handful of previous studies that aimed to
identify the transcriptional programme driven by Wnt signal-
ling. Most of these studies have been based on messenger ribo-
nucleic acid (mRNA) expression microarray analysis. The
methods and systems used have been very variable, and
have included inactivation of Wnt in colorectal cancer
(CRC) cell lines, activation of Wnt in cell lines from normal
intestinal epithelium and study of colorectal tumours (benign
and malignant) from humans. Most studies have been
focused on human tumours. Perhaps unsurprisingly, there
has been considerable variation between studies in their detec-
tion of known Wnt targets and in their identiﬁcation of new
targets. Thus, despite some notable successes, it has some-
times proved difﬁcult to distinguish signal from noise. Reichl-
ing et al. (2) undertook transcriptional proﬁling of 14 Apc
Min
mouse adenomas and found 114 differentially expressed
genes, excluding known Wnt targets. When analysis of
CRCs was added, differential expression of genes such as
Igfbp5, Lcn2, Ly6d, N4wbp4 (PMEPA1), S100c and Sox4
was found. Van der Flier et al. (1) expressed dominant-
negative TCF4 or TCF1 in CRC cell lines DLD1 and
LS174T. Changes were conﬁrmed in 32 human adenomas
and 25 CRCs. Consistently down-regulated genes (putative
positive Wnt targets) included AXIN2, MYC, ASCL2, LGR5/
GPR49, HIG2, BMP4 and SOX4. Kaiser et al. (3) compared
gene expression proﬁles in embryonic colon and colorectal
tumours and found signiﬁcant resemblances between them.
Sabates-Bellver et al. (4) undertook transcriptome proﬁling
of human colorectal adenomas from 32 patients. After micro-
enrichment for epithelium, 319 possible positive and negative
Wnt targets were identiﬁed by expression proﬁling. Of these,
144 genes displayed signiﬁcantly altered expression on veriﬁ-
cation. The KIAA1199 gene was particularly highly expressed
(60-fold increased). Gaspar et al. (5) studied 42 polyps from
13 patients (eight APC- and ﬁve MYH-mutant) with three
normal samples for comparison. Duodenal adenomas from
three Apc
1638N mice and two wild-type mice were also ana-
lysed. Approximately 10% of 18 000 genes were differentially
expressed in humans and, after analysis of the mouse samples,
a 166-gene signature (100 up, 66 down) was derived, yet this
included only a few known Wnt targets. Immunohistochemis-
try was used to validate CD44, ANXA1, CCNA2 and
MARCKSL1.
We aimed to identify mRNAs that were consistently differ-
entially expressed between early adenomas and morphologi-
cally normal tissue from both humans and mice. We
therefore collected a much larger sample of mouse tumours
for analysis than previous studies had done. In order to
utilize a relatively homogeneous system and to ensure that
tumorigenesis was driven by ‘second hits’ at APC,w e
focused on individuals with known germline APC mutations,
either humans with familial adenomatous polyposis (FAP) or
mice with the Apc
Min(R850X) mutation. Adenomas were early
lesions (,5 mm diameter, tubular morphology, mildly dys-
plastic), and a small number of sporadic human CRCs was
analysed alongside them. Using stringent criteria, we ident-
iﬁed a number of genes that are differentially expressed in
early colorectal tumours and represent strong candidates as
direct or indirect targets of Wnt signalling. We discuss these
data in the light of previous studies.
RESULTS AND DISCUSSION
Expression proﬁling and veriﬁcation
Using a stringent signiﬁcance threshold of P , 0.005 after
Benjamini–Hochberg false discovery rate (FDR) correction,
we identiﬁed 220 genes that were signiﬁcantly up-regulated
and 548 that were signiﬁcantly down-regulated by at least
2-fold when comparing normal tissue and large-bowel adeno-
mas from human FAP patients. If multiple probes from one
gene were present on the array, we scored that gene as differ-
entially expressed if any probe fulﬁlled our criteria, although
in no case were two different probes from the same gene sig-
niﬁcantly altered in opposite directions. The 768 genes are
shown in Supplementary Material, Table S1. The list included
several genes that have been described as direct or indirect
targets of Wnt signalling, including CCND1, CD44, CLU,
EPH receptors, LGR5/GPR49, MMP7, MYC and SFRP1.
Absent from the list, because they were not signiﬁcantly
differentially expressed, were known Wnt targets such as
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up-regulated gene was CDH3 (P-cadherin), which was over-
expressed 35-fold.
We then compared the list of human genes with genes that
passed the same thresholds in three series of large and small
bowel adenomas from Min mice on the C57BL/6J background
(see Materials and Methods). In line with our stringent selec-
tion process, initial ﬁltering required .95% of all mouse
probes from all three series of polyps to show changes in
the same direction as the human changes. Evidently, this strat-
egy will have excluded some genuine direct or indirect Wnt
targets, especially those-speciﬁc to each species or to different
regions of the bowel, or those with sub-optimal probes on the
arrays. Other genes, such as CD44, showed 10% of discor-
dant probes, presumably as a result of isoform-speciﬁc
expression in the two species. TCF4 and CLU (clusterin)
showed an unusual pattern, with universal up-regulation in
mice, but down-regulation in all human tumours.
We then excluded all genes for which no mouse probe
showed signiﬁcantly changed expression at P , 0.005. In
practice, this selection largely excluded genes with few
probes on the arrays and for which there was consequently
low conﬁdence in the expression changes being consistent in
humans and mice. This reduced the list to a ‘gene expression
signature’ of 60 up-regulated and 151 down-regulated genes
(Table 1). This gene set included the up-regulated targets
CCND1, EPHB2, EPHB3, LGR5, MMP7 and MYC and the
down-regulated SFRP1. The most up-regulated gene was
TACSTD2 (18-fold in humans, 82-fold in mouse) and the
most down-regulated were CCL19 (25-fold in humans) and
Cnn1 (33-fold in mouse). The genes performed no evident
common function (apart from being in the Wnt pathway in
some cases), although some related genes were present in
the list, an example being GREM1 and GREM2.
In order to validate the expression array data, we then selected
for quantitative reverse transcription polymerase chain reaction
(qRT–PCR) analysis a mixture of 22 differentially expressed
genes showing up- or down-regulation (described later), includ-
ing some known Wnt targets and some potentially novel
targets. These genes were studied in additional sets of up to 19
FAP large bowel adenomas, seven sporadic human CRCs, 14
Min mouse small bowel adenomas, and 19 Min mouse large
bowel adenomas. Actual sample numbers studied for each gene
varied according to the quantity of mRNA extracted from each
lesion (see Materials and Methods). Pre hoc, our criteria were
to reject any gene for which any of the sample sets showed an
expression change in the opposite direction to that found by
microarray analysis and also to exclude any gene that did not
show a signiﬁcant expression difference (at P , 0.05 to reﬂect
fewer tests) in any sample type. In practice, almost all genes
passed these thresholds. We successfully validated the array
data for the following up-regulated genes: MMP7, LGR5,
MYC, CCND1, ITGA6, PHLDA1, CXCL3, IER3, TGIF,
SEMA3F, SOX4, TACSTD2 and HOXA9.H o w e v e r ,ETS2 was
only over-expressed in adenomas, and actually signiﬁcantly
under-expressed in two of the three CRCs investigated. For
down-regulated genes, we validated under-expression of SGK1,
GNA11, SFRP1, RARRES2, HPGD and MAB21L2.H o w e v e r ,
whilst GREM1 and GREM2 were under-expressed in adenomas,
these two genes showed increased expression in CRCs. In
summary, all targets were successfully veriﬁed in adenomas,
but in a small number of cases, gene expression levels changed
on progression to carcinoma.
In situ analysis of gene expression
We then undertook in situ hybridization (ISH) of mRNAs using
normal intestinal epithelium and adenomas from FAP patients
and Min mice, in order to determine the topographical
expression patterns of a subset of the consistently changed
genes. Although it is difﬁcult to make truly quantitative com-
parisons between gene expression levels using ISH, it is possible
to make semi-quantitative comparisons using the beta-actin
control probe, to assess the gradient of expression of any gene
along the crypt axis, and to assess the cell types in which
genes are principally expressed. In some cases, expression
levels were low and reliable ISH data could not be obtained.
However, clear results were obtained in the following cases.
We ﬁrst analysed some established Wnt targets. MYC and
EPHB2 were strongly expressed in the transit amplifying
zone of normal crypts (type 1 genes), and throughout the epi-
thelium of adenomas. MMP7 was strongly expressed only at
the bases of normal crypts, but strongly or moderately diffu-
sely in adenoma epithelium; expression appeared to be par-
ticularly strong in Paneth cells, but was not restricted to this
lineage and MMP7 could therefore be classed as of mixed
type 2/3. CD44 was moderately/strongly expressed at the
crypt bases (and in villus cores of normal small bowel epi-
thelium), and strongly in adenomas (type 3). CCND1
(assessed using immunohistochemistry) was principally
expressed in the transit amplifying zone of normal crypts
and widely in adenomas, with the strongest expression near
the crypt tops.
LGR5 encodes an orphan G-protein coupled receptor and
was originally identiﬁed as a Wnt target in CRC cell lines.
It was shown to be up-regulated in hepatocellular carcinomas
carrying beta-catenin mutations (6) and in colorectal and
ovarian tumours (7). It has been reported as being expressed-
speciﬁcally in crypt base columnar (CBC) cells, between the
Paneth cells, by Barker et al. (8). On this basis, coupled
with lineage tracing, LGR5 has been proposed as a crypt
stem (or progenitor) cell marker. We too found LGR5 to be
a type 3 gene, with expression restricted to the crypt bases,
especially the CBC cells, in both large and small bowel. In
adenomas, LGR5 was generally present in patches of variable
size that comprised about two-thirds of the total area of the
lesion (Fig. 1A), more extensive than reported by Barker
et al. (8). In general, these areas were close to the adenoma
core, consistent with retention of some normal crypt hierarchy,
some differentiation towards the surface of early adenomas,
and a ‘bottom-up’ model of adenoma pathogenesis.
SGK1 encodes a kinase involved in the control of ion trans-
port. It was expressed at the tops of normal crypts (Fig. 1B)
and on villi, but was absent from all adenomas and carci-
nomas. Naishiro et al. (9) had found decreased expression of
SGK1 mRNA in a rat intestinal epithelial cell line that
expressed a stable form of beta-catenin. Immunohistochemis-
try by Naishiro et al. (9) did not conﬁrm the mRNA expression
data, but in our hands, SGK1 antibodies have proved unsuita-
ble for use in ﬁxed material. Interestingly, SGK1 expression
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Direction Human Mouse Gene symbol Gaspar et al. Van der
Flier et al.
adenomas
Sabates-Bellver et al. Hatzis et al. Our
Wnt Fold
change
P-value Fold
change
P-value
Up 17.65 0.0001 82.22 0.0010 TACSTD2  NNN Y N
Up 10.91 0.0000 11.05 0.0000 DUSP4 N N N Y
Up 8.62 0.0000 36.12 0.0010 MMP7  YNN N
Up 7.60 0.0025 1.19 0.0010 SERPINB5 N N N N
Up 7.40 0.0000 1.95 0.0010 GDF15 N N N Y
Up 7.37 0.0007 49.64 0.0010 CXCL3  YNN Y N
Up 5.92 0.0001 4.56 0.0010 GPR49/LGR5  NYY N Y
Up 5.89 0.0000 28.15 0.0010 CXCL1 Y N Y N
Up 5.84 0.0005 1.16 0.0010 FABP6 N N N N
Up 4.99 0.0000 1.29 0.0010 SLC12A2 Y N N Y
Up 4.33 0.0000 2.29 0.0010 ITGA6  YNN Y N
Up 3.99 0.0000 3.03 0.0010 EPHB3 Y Y N Y
Up 3.91 0.0000 7.72 0.0001 FLJ20315 N Y N N
Up 3.88 0.0005 1.29 0.0010 HYAL1 N N N N
Up 3.47 0.0003 1.32 0.0010 EPHB2 N Y N Y
Up 3.10 0.0034 2.22 0.0005 DDX31 N N N N
Up 2.99 0.0000 4.47 0.0010 SEMA3F  NNN Y N
Up 2.95 0.0025 1.65 0.0010 HOXA9  NNN N
Up 2.90 0.0004 8.43 0.0010 PHLDA1  YYY Y N
Up 2.82 0.0001 7.91 0.0010 SOX4  YYN N
Up 2.79 0.0006 2.28 0.0010 ETS2  YYN Y N
Up 2.74 0.0001 9.95 0.0005 C9orf26 N N N N
Up 2.73 0.0004 1.34 0.0010 CCT2 N N N N
Up 2.72 0.0047 1.42 0.0041 FLJ10458 N N N N
Up 2.63 0.0003 2.39 0.0010 S100A11 N N Y N
Up 2.63 0.0002 2.03 0.0001 GTF2IRD1 Y N N N
Up 2.53 0.0008 4.64 0.0024 TRIM29 N N N N
Up 2.48 0.0006 1.07 0.0010 APG-1 N N N N
Up 2.46 0.0027 2.95 0.0010 MYC  NYN Y
Up 2.45 0.0004 1.71 0.0010 CGI-07 N N N N
Up 2.41 0.0003 2.95 0.0010 TGIF  NYN Y
Up 2.41 0.0000 2.02 0.0012 SH3BP4 N N N Y
Up 2.37 0.0004 1.59 0.0010 ABCE1 Y N N N
Up 2.37 0.0002 1.98 0.0010 SLC39A8 N N N Y
Up 2.34 0.0040 2.02 0.0010 ZNF22 N N N N
Up 2.33 0.0018 1.71 0.0001 FAIM N N N N
Up 2.31 0.0002 1.13 0.0010 RGNEF N N N N
Up 2.29 0.0002 3.05 0.0010 CCND1  YNN Y
Up 2.25 0.0025 9.25 0.0010 IER3  NNN N
Up 2.22 0.0004 2.14 0.0002 SOX9 N Y N N
Up 2.16 0.0019 2.21 0.0010 MEP50 N N N N
Up 2.16 0.0046 1.51 0.0010 CDC2 Y N N N
Up 2.14 0.0050 2.14 0.0132 TOPK N N N N
Up 2.14 0.0003 3.00 0.0260 RHOBTB3 N Y N N
Up 2.12 0.0000 3.37 0.0000 PLEK2 N N N N
Up 2.11 0.0003 1.43 0.0010 BTG3 N N N N
Up 2.11 0.0005 1.82 0.0010 SLC39A6 N N N N
Up 2.10 0.0032 1.40 0.0010 HSPD1 N N N N
Up 2.10 0.0017 1.25 0.0010 TRIP6 Y N N N
Up 2.09 0.0022 1.77 0.0010 DTYMK N N N N
Up 2.07 0.0048 1.37 0.0010 NPM1 N N N N
Up 2.07 0.0011 1.04 0.0010 GCSH N N N N
Up 2.06 0.0034 1.15 0.0010 IPO7 Y N N N
Up 2.04 0.0020 1.45 0.0010 RRS1 N N N N
Up 2.04 0.0005 1.50 0.0010 CKAP2 N N N N
Up 2.02 0.0025 1.07 0.0010 RCN2 N N N N
Up 2.02 0.0005 2.44 0.0001 AASDHPPT N N N N
Up 2.02 0.0032 1.02 0.0010 PMPCB N N N N
Up 2.01 0.0018 4.13 0.0010 TM4SF12 N N N N
Up 2.00 0.0001 3.07 0.0011 DUSP14 N N N N
Down 24.75 0.0000 1.60 0.0010 CCL19 Y N N
Down 16.47 0.0000 1.79 0.0010 CCL21 N N N
Down 12.82 0.0000 1.69 0.0010 FY N N N
Down 11.47 0.0004 33.20 0.0010 CNN1 N Y N
Down 10.25 0.0000 3.49 0.0010 CXCL12 N N N
Continued
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Direction Human Mouse Gene symbol Gaspar et al. Van der
Flier et al.
adenomas
Sabates-Bellver et al. Hatzis et al. Our
Wnt Fold
change
P-value Fold
change
P-value
Down 9.31 0.0000 17.72 0.0010 TNA N N N
Down 8.97 0.0001 1.98 0.0010 CXCL13 N N Y
Down 8.92 0.0001 2.81 0.0010 GCG N N Y
Down 8.59 0.0001 1.25 0.0010 MAP4K1 N N N
Down 7.92 0.0000 2.63 0.0010 RTN1 N Y N
Down 7.81 0.0014 1.02 0.0010 CCL22 N N N
Down 7.67 0.0001 10.94 0.0010 TAGLN  NN N
Down 7.66 0.0001 8.91 0.0010 ADH1B N N N
Down 7.06 0.0001 1.24 0.0008 PPP1R16B Y N Y
Down 6.96 0.0000 12.96 0.0010 TNXB N N N
Down 6.69 0.0000 7.60 0.0010 GREM2  N N N Too low
Down 6.65 0.0000 1.18 0.0010 RASGRP2 N N N
Down 5.90 0.0000 6.70 0.0010 MYLK Y Y N
Down 5.85 0.0042 1.30 0.0003 CRYBA2 N N N
Down 5.81 0.0000 4.65 0.0010 ABCG2 Y N N
Down 5.59 0.0000 1.02 0.0010 CCR7 N N N
Down 5.36 0.0001 8.46 0.0010 CA1 Y N Y
Down 5.28 0.0001 3.35 0.0010 HLA-DQA1 ///
HLA-DQA2
NN N
Down 5.14 0.0001 1.52 0.0010 ADAMDEC1 N N N
Down 5.11 0.0000 1.32 0.0010 CD22 N N N
Down 5.06 0.0000 1.11 0.0463 CA7 N N N
Down 4.83 0.0000 2.83 0.0067 SCGN N N N
Down 4.82 0.0001 1.92 0.0010 RHOH N Y N
Down 4.76 0.0001 5.75 0.0010 CHGA Y N N
Down 4.74 0.0001 1.14 0.0010 SFRP1  YY N
Down 4.72 0.0034 3.73 0.0010 MAB21L2  NN N
Down 4.71 0.0001 1.67 0.0010 INSM1 Y N N
Down 4.69 0.0000 1.30 0.0307 P2RX5 N N N
Down 4.69 0.0000 1.24 0.0010 LSP1 N N N
Down 4.69 0.0000 2.51 0.0010 RARRES2  NN N N
Down 4.64 0.0019 1.28 0.0018 BRDG1 N Y N
Down 4.62 0.0001 1.27 0.0218 KIAA0657 N N N
Down 4.60 0.0003 2.01 0.0010 BCHE N N N
Down 4.35 0.0001 1.85 0.0010 FOLR2 N N N
Down 4.31 0.0000 5.56 0.0019 PDE2A N N N
Down 4.29 0.0001 1.28 0.0010 CD7 N N N
Down 4.10 0.0037 1.45 0.0010 ANPEP N N N
Down 4.07 0.0000 1.85 0.0010 DSIPI N N N
Down 4.04 0.0003 3.15 0.0010 TNFRSF17 N Y N
Down 4.01 0.0001 1.29 0.0010 RAC2 N N N
Down 4.00 0.0001 1.44 0.0010 NR3C1 N Y N
Down 3.99 0.0003 1.06 0.0010 GREM1  N N N Too low
Down 3.96 0.0001 1.35 0.0010 XLKD1 N Y N
Down 3.96 0.0012 1.66 0.0010 AIF1 N N N
Down 3.92 0.0006 1.91 0.0010 LTB N N N
Down 3.84 0.0000 1.77 0.0010 CD79A Y N N
Down 3.82 0.0000 1.70 0.0010 POU2AF1 N N Y
Down 3.81 0.0010 1.30 0.0007 DKFZP434C171 N N N
Down 3.81 0.0000 33.73 0.0010 CES1 N N N
Down 3.81 0.0000 1.86 0.0010 HSPB2 N N N
Down 3.80 0.0000 1.68 0.0010 CD48 N Y N
Down 3.76 0.0014 1.46 0.0010 PCSK2 N N N
Down 3.72 0.0001 1.34 0.0010 KLF2 N N Y
Down 3.68 0.0001 1.28 0.0003 OLFML3 N N N
Down 3.65 0.0003 2.21 0.0010 CD79B N N N
Down 3.49 0.0020 5.22 0.0010 PTPRR N Y N
Down 3.47 0.0009 1.54 0.0010 SELL N N N
Down 3.42 0.0000 2.22 0.0010 HLA-DRB1 Y N N
Down 3.41 0.0022 5.30 0.0010 CCL5 N Y N
Down 3.40 0.0018 1.71 0.0010 LRMP N N N
Down 3.35 0.0009 1.55 0.0005 TTID N N N
Down 3.31 0.0005 2.45 0.0010 KCTD12 N Y N
Down 3.29 0.0001 12.81 0.0015 ITIH5 N Y N
Continued
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Direction Human Mouse Gene symbol Gaspar et al. Van der
Flier et al.
adenomas
Sabates-Bellver et al. Hatzis et al. Our
Wnt Fold
change
P-value Fold
change
P-value
Down 3.28 0.0002 2.63 0.0010 COL13A1 N N N
Down 3.22 0.0003 1.70 0.0010 GIMAP4 N N N
Down 3.17 0.0007 1.14 0.0010 WASPIP Y N N
Down 3.15 0.0001 1.32 0.0005 MAP1B N N Y
Down 3.14 0.0004 11.87 0.0001 TRPM6 N N N
Down 3.13 0.0003 1.10 0.0010 AKAP12 N Y N
Down 3.07 0.0008 3.79 0.0010 FXYD1 N Y N
Down 3.04 0.0000 5.83 0.0010 PCK1 N N N
Down 3.03 0.0004 5.68 0.0007 RODH N N N
Down 3.02 0.0025 1.25 0.0010 MS4A1 N N N
Down 2.99 0.0000 2.62 0.0010 CD74 N N N
Down 2.98 0.0007 2.63 0.0010 CEACAM1 Y N N
Down 2.96 0.0035 22.47 0.0010 CA4 N N N
Down 2.95 0.0000 22.17 0.0001 DPYD N N N
Down 2.94 0.0004 1.41 0.0019 SLAMF8 N N Y
Down 2.94 0.0000 2.22 0.0010 HLA-DRB3 N N N
Down 2.91 0.0004 1.60 0.0010 GMFG N N N
Down 2.84 0.0009 2.64 0.0010 TCF21 N N N
Down 2.84 0.0008 1.77 0.0010 L1CAM N Y N
Down 2.80 0.0004 1.78 0.0010 EDN3 Y N N
Down 2.79 0.0023 8.91 0.0010 ADH1C ///
ADH1A ///
ADH1B
NN N
Down 2.79 0.0001 1.87 0.0010 ZBTB16 N N Y
Down 2.76 0.0000 1.07 0.0010 PALM2-AKAP2 N N N
Down 2.76 0.0001 2.52 0.0010 EDG2 N Y Y
Down 2.75 0.0026 6.75 0.0005 LOC63928 N Y N
Down 2.75 0.0000 1.16 0.0010 ITGB2 N N N
Down 2.74 0.0036 4.29 0.0000 OSR2 N N N
Down 2.73 0.0003 1.04 0.0010 SEP06 N N N
Down 2.72 0.0019 1.35 0.0105 BC008967 N N N
Down 2.70 0.0000 2.54 0.0010 GNA11  YN N N
Down 2.69 0.0000 1.82 0.0010 IL6R Y Y Y
Down 2.69 0.0025 2.02 0.0010 PLTP N N N
Down 2.67 0.0005 4.34 0.0010 CCL8 N Y N
Down 2.66 0.0001 2.02 0.0010 SLC4A4 Y N N
Down 2.61 0.0047 1.57 0.0010 PTPRCAP N N N
Down 2.61 0.0019 1.20 0.0010 NNMT N N N
Down 2.61 0.0004 1.41 0.0010 IL7R N N N
Down 2.60 0.0017 1.69 0.0010 CD8A N N N
Down 2.59 0.0000 1.80 0.0010 RASSF2 N N N
Down 2.59 0.0004 1.33 0.0010 CD19 N N N
Down 2.59 0.0006 1.55 0.0152 HOM-TES-103 N N N
Down 2.58 0.0025 10.77 0.0010 HPGD  YY Y
Down 2.57 0.0001 5.71 0.0010 UPP1 N N N
Down 2.52 0.0001 8.17 0.0001 MGC4172 Y Y N
Down 2.51 0.0007 2.98 0.0010 BTK N N N
Down 2.49 0.0020 3.15 0.0010 HLA-DQB2 N N N
Down 2.49 0.0032 1.64 0.0010 LAT N N N
Down 2.46 0.0050 3.42 0.0010 MFAP5 N N N
Down 2.46 0.0020 2.71 0.0010 SGK1  YN N N
Down 2.45 0.0003 1.13 0.0006 SAMSN1 N N Y
Down 2.44 0.0000 1.65 0.0010 FCGRT N N N
Down 2.43 0.0021 1.66 0.0010 PER1 N N Y
Down 2.41 0.0011 1.30 0.0010 PPAP2B N N Y
Down 2.41 0.0046 2.03 0.0010 RECK N N N
Down 2.41 0.0042 1.07 0.0010 C1QA N N N
Down 2.39 0.0001 4.99 0.0010 HLA-DMB N N N
Down 2.38 0.0046 6.46 0.0025 CLDN15 N N N
Down 2.37 0.0042 11.61 0.0010 KCNMB1 N N N
Down 2.36 0.0001 6.55 0.0031 BENE N N N
Down 2.36 0.0000 1.94 0.0010 AQP1 Y N N
Down 2.34 0.0002 1.21 0.0010 ITK N N N
Down 2.30 0.0001 1.24 0.0010 CD2 N N N
Continued
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types (10,11) and recently, Dehner et al. (12) found SGK1 to
be up-regulated in the CRC cell line HCT116 when Wnt sig-
nalling was increased by knock-down of APC. However, we
have found that SGK1 expression in colorectal carcinomas is
very low, consistent with its role in ion transport which
suggests that higher expression is expected at the top of the
crypt and on the villus. Intestinal stem cells, adenomas and
CRCs would not be expected to express SGK1, consistent
with our data.
GNA11 is a G-protein of essentially uncertain function in
the gut. It is probably involved in transmembrane signalling
and may act as an activator of phospholipase C. Down-
regulation of the gene has been demonstrated in breast
cancers (13). GNA11 showed moderate expression in normal
epithelium, without any clear gradient or obvious restriction
of expression. Expression was universally down-regulated in
adenomas (Fig. 1C).
ETS2 is a transcription factor that recognizes the core con-
sensus deoxyribonucleic acid (DNA) sequence GGAA/T
upstream of target genes. ETS2 was expressed at the base
and in the lower third of the transit amplifying zone of
normal crypts. Adenomas investigated by ISH showed gener-
ally increased expression, with a subtle falling-off of levels
towards the tops of crypts (Fig. 1D). Interestingly, Sussan
et al. (14) showed that trisomy 21 repressed intestinal tumori-
genesis largely through ETS2 over-expression. In line with this
effect, ETS2 may play a role in promoting apoptosis (15), and
intestinal adenomas exhibit increased rates of apoptosis (our
unpublished data). ETS2 is over-expressed in several types
of cancer, although out of the three sporadic colorectal
carcinomas we investigated by qRT–PCR, only one showed
3.5-fold up-regulation of the gene, while the other two
showed decreased expression (1.6 and 9.0-fold respectively),
suggesting that its functional effects may be context-dependent.
GREM1 and GREM2 were expressed at relatively low levels
in the sub-epithelial myoﬁbroblasts and muscularis mucosa of
the normal intestinal epithelium. Expression was not detect-
able in adenomas. These proteins are secreted bone morpho-
genetic protein (BMP) antagonists that are 55% identical to
each other within a 173 amino acid core. An SNP near
GREM1 is associated with increased risk of CRC in humans
(16). The pattern of Gremlin expression in normal tissue
(Fig. 1E) partially resembles that detected previously by
Kosinski et al. (17) who compared gene expression in the
tops and bottoms of crypts. It is also strongly suggestive of
a BMP gradient along the crypt, with levels highest at the
top and lowest near the stem cells at the bottom. However,
we and others (18,19) have found increased Gremlin
expression in cancers, apparently at odds with decreased
expression in our adenomas. It is possible that these obser-
vations reﬂect a decreased ratio of muscularis mucosa to epi-
thelium in benign lesions, but a tendency for malignancies to
acquire their own Gremlin expression—and perhaps a
mesenchyme-like phenotype—in order to maintain a stem
cell-like state independent of the surrounding tissues.
ITGA6 is a member of the integrin alpha subunit family
involved in cell adhesion and signalling. Up-regulation of
the gene has been identiﬁed in oesophageal adenocarcinomas
(20) and was found to be necessary for survival of a highly
tumorigenic sub-population of breast cancer cells, through
roles in adhesion and/or signalling (21). ITGA6 mRNA
Table 1. Continued
Direction Human Mouse Gene symbol Gaspar et al. Van der
Flier et al.
adenomas
Sabates-Bellver et al. Hatzis et al. Our
Wnt Fold
change
P-value Fold
change
P-value
Down 2.30 0.0022 2.36 0.0010 CD3Z Y N N
Down 2.29 0.0001 1.58 0.0008 BACH2 N N Y
Down 2.21 0.0001 3.42 0.0010 NR5A2 Y Y N
Down 2.19 0.0040 1.15 0.0010 CD160 N N N
Down 2.19 0.0028 8.32 0.0010 PCSK1N N N N
Down 2.17 0.0021 2.14 0.0235 CHRNA3 N N N
Down 2.16 0.0009 1.68 0.0010 HCK N N N
Down 2.14 0.0042 3.28 0.0010 – N N N
Down 2.13 0.0003 1.29 0.0010 MXI1 Y N Y
Down 2.10 0.0020 1.91 0.0000 PDLIM2 N N N
Down 2.08 0.0047 1.34 0.0010 CSF1R N N N
Down 2.06 0.0046 1.48 0.0010 HOXD4 Y N N
Down 2.05 0.0013 1.88 0.0010 CXCL9 N N Y
Down 2.04 0.0012 9.81 0.0005 FLJ21934 N N N
Down 2.03 0.0011 5.44 0.0010 SLC26A2 Y Y N
Down 2.03 0.0006 17.87 0.0004 CLIC5 Y N N
Down 2.02 0.0047 2.58 0.0061 FLJ11000 N N N
Down 2.02 0.0012 12.55 0.0010 CHGB N N N
Down 2.02 0.0022 1.60 0.0010 EZH1 N N N
Down 2.00 0.0022 1.10 0.0010 GZMA N N N
Down 2.00 0.0011 1.05 0.0010 KCNH2 N N N
The table shows genes with consistent expression across all of our human and mouse series. Genes investigated further are indicated by asterisk mark.
Data from the ‘signatures’ of the three other similar studies are shown for each gene in our list (Y ¼ present in other signature, N ¼ not present). The
promoter TCF-binding data of Hatzis et al. are also shown similarly, and ﬁnally the results of our experiment to determine whether the genes are direct
Wnt targets.
3870 Human Molecular Genetics, 2008, Vol. 17, No. 24expression was essentially absent in normal intestine, but there
was strong up-regulation throughout adenomatous epithelium
(Fig. 1F).
RARRES2 showed an unusual change between normal tissue
and adenomas. In the normal crypt, expression was concen-
trated around the base (Fig. 1G). Although there was a net
decrease in RARRES2 expression in adenomas, it became
more widespread, involving the whole epithelium at a low
level (Fig. 1H). RARRES2 is a retinoic acid receptor, although
its function is poorly described.
Comparison and pooled analysis with other studies
We compared our data with those of three relatively large
studies that have been published (1,4,5), although one of
these studies (1) only reported genes that were up-regulated
when Wnt was activated. Of our 60 þ 151 ‘gene signature’,
19% of genes were present in the Gaspar data set (1859
genes with FDR , 0.005), 18% in the van der Flier data set
(160 up-regulated genes with FDR , 0.05) and 14% in the
Sabates-Bellver data (genes with .4-fold expression differ-
ence and FDR , 0.01). By way of comparison, 16% of the
genes reported by van der Flier et al. were also present in
the list of Gaspar et al. The following up-regulated genes
were present in our list and at least two of the other lists:
GPR49/LGR5, EPHB3, PHLDA1, SOX4 and ETS2. A further
17 up-regulated genes, including MYC and CCND1, were
present in our list and in one other list. For our down-regulated
genes, 44 (including GNA11 and SGK1) were present in at
least one of the other two studies, and seven (MYLK,
SFRP1, IL6R, HPGD, MGC4172, NR5A2 and SLC26A2)
were listed in all three studies. Thirty-seven genes were
unique to our list, including the following that were conﬁrmed
by qRT–PCR: TACSTD2, SEMA3F, HOXA9 and IER3 (all
up), and TAGLN, GREM1, GREM2, MAB21L2 and
RARRES2 (all down).
Figure 1. In situ hybridization analysis of selected genes showing differential expression in APC-mutant adenomas and normal tissue. Representative images
(human adenomas unless otherwise stated) of ISH ( 20 magniﬁcation) for Gpr49/Lgr5 (mouse adenoma shown, A), SGK1 (B), GNA11 (C), ETS2 (D), GREM2
(normal tissue only, E), ITGA6 (F) and RARRES2 (normal tissue, G and adenoma, H). Left panels of each pair are Giemsa-stained sections. Right panels are
dark-ﬁeld images highlighting autoradiographic silver. Solid lines on Giemsa-stained images delineate tumour tissue. White solid arrows on dark ﬁeld images
illustrate gene expression in tumour tissue. Dashed arrows indicate gene expression in normal tissue.
Human Molecular Genetics, 2008, Vol. 17, No. 24 3871Since our sequential ﬁltering strategy favours-speciﬁcity at
potentially great cost in sensitivity, we also undertook a
pooled analysis of our human data and the publicly available
results of Sabates-Bellver et al. (4) who used an Affymetrix
platform which was compatible with our analysis. A combined
analysis of our data from human FAP adenomas with those of
Sabates-Bellver was performed, with the caveat that APC
mutation status was not characterized in the Sabates-Bellver
sample set. The 1676 genes with a .2-fold difference in
expression, using a FDR threshold of 0.001 and after correc-
tion for variation between experiments, are shown in Sup-
plementary Material, Table S3. The combined analysis
conﬁrmed most of the putative Wnt targets reported in this
study and previously. In addition, the following targets were
of note and were supported in both studies. CDH3, highly
expressed in our human data but not universally so in mouse
tumours and not reported in all other studies, was strongly sup-
ported by the combined analysis. Similarly, KIAA1199
reported as a possible Wnt target by Sabates-Bellver et al.,
was also over-expressed in our study and supported by the
combined analysis. BMP expression, with the exception of
BMP4, was generally decreased, despite the decrease in
expression of the BMP antagonists GREM1 and GREM2.
This may favour a stem cell phenotype, but appears to be a
paradoxical result, and may be secondary to changes in the
Gremlins. Hypoxia pathway components, such as carbonic
anhydrases, were also generally decreased. Other previously
unreported, but potentially interesting targets included the
spindle assembly checkpoint genes BUB1 and BUB1B,
which were over-expressed; given that APC has a proposed
(though controversial) role in chromosomal instability
through chromosome mis-segregation, it is possible that
BUB1/BUB1B are over-expressed in response to mitotic
checkpoint activation (22).
Differential expression and TCF-binding
In order to test whether some of our differentially expressed
genes were direct Wnt targets, we searched using Fuzznuc
from Emboss for the presence of putative TCF4-binding
sites (WWCAAWG) in the 10 kb upstream of the translation
start site of each transcript in humans (data from https://
www.ensembl.org/). We examined whether genes with signiﬁ-
cant expression differences in human tumours tended to have
more upstream TCF4 sequences than genes without such
differences.-speciﬁcally, in a logistic regression analysis, we
set as the dependent variable whether a gene was signiﬁcantly
differentially expressed and used as independent variables: (i)
distance from the translation start site in 500 bp bins, (ii) mean
number of TCF4-binding motifs in each bin over all genes,
and (iii) local GC content in that bin. The mean number of
TCF4 sequences was signiﬁcantly higher (P ¼ 0.001) for
signiﬁcantly differentially expressed genes (mean ¼ 0.68 per
gene) than other genes (mean ¼ 0.62), even after stratifying
for local GC content. There was overall no effect of distance
from translation start site on motif frequency, although it
was notable that the ﬁrst 500 bp upstream, which was
GC-rich and hence least likely to have TCF4-binding motifs
that occurred by chance, showed the highest difference
between signiﬁcantly and non-signiﬁcantly differentially
expressed genes (means 0.46 and 0.39 binding sites per gene
respectively, P , 0.0001, Wilcoxon test).
We tested whether some-speciﬁc members of our Wnt
‘signature’ were likely to be direct targets. We used the
CRC cell line RKO in which Wnt signalling is not active
and, owing to reported issues of toxicity if beta-catenin is
over-expressed in these cells, we activated Wnt signalling
using LiCl, an inhibitor of GSK3-beta. New protein synthesis
was inhibited using cycloheximide. We found that GREM1
and GREM2 were already expressed at very low levels prior
to Wnt activation, consistent with their origins from
non-epithelial cells. LGR5 showed 2.1-fold increased
expression, consistent with it being a direct positive Wnt
target. However, all of the other genes tested (CXCL3,
ETS2, GNA11, ITGA6, PHLDA1, SEMA3F, SGK1,
TACSTD2) showed less than the conventional threshold of
1.5-fold change in mRNA levels, suggesting that they are
not direct positive or negative Wnt targets.
We then determined whether our ‘Wnt signature’ genes had
been detected as possible targets of TCF4/beta-catenin binding
using chromatin immunoprecipitation assays in the study of
Hatzis et al. (23). We examined the top 2148 genes reported
by Hatzis et al., containing a total of 6868 high-conﬁdence
binding sites. Of the 21 most strongly over-expressed genes
in our human tumours (Table 1), 11 had high-conﬁdence
TCF4 -binding sites (TACSTD2, DUSP4, GDF15, CXCL3,
SLC12A2, ITGA6, EPHB3, EPHB2, SEMA3F, PHLDA1 and
ETS2). In all, 16/60 over-expressed genes, but only 18/151
under-expressed genes, were associated with binding sites
(P ¼ 0.0086, x
2
1 test). Whilst the possibility of direct negative
Wnt targets cannot be excluded, this result conﬁrms that Wnt
activation generally leads to increased direct target expression.
It also suggests that some positive Wnt target genes—such as
TACSTD2 and SEMA3F, which were not over-expressed when
we activated Wnt in the absence of new protein synthesis—
may contain TCF4-binding sites that are not involved in
causing increased gene expression in vivo.
Concluding remarks
Using high-stringency ﬁltering, we have identiﬁed a set of 60
up-regulated and 151 down-regulated genes that show consist-
ent expression differences between intestinal adenomas and
normal tissue from humans and mice. This list includes
known Wnt targets. The remaining ‘novel’ genes are potential
Wnt targets, mostly of the indirect type, but many are likely to
be indirectly inﬂuenced by Wnt or by the cellular composition
of adenomas compared with normal epithelium. All genes
tested that were differentially expressed by microarray analy-
sis were conﬁrmed by qRT–PCR. However, ISH showed that
the actual localization of the differentially expressed mRNAs
was highly variable. In situ analysis is therefore very import-
ant when examining genes with differential expression in early
intestinal tumours.
It is notable that the several studies to identify putative Wnt
targets using mRNA expression analysis in colorectal tumours
have found only limited overlap. Inevitably, some ‘targets’ are
false-positives, but the differences also reﬂect the use of
different samples and mechanisms of Wnt activation, and
different methods of analysis. For example, we deliberately
3872 Human Molecular Genetics, 2008, Vol. 17, No. 24excluded some differentially expressed genes for which
mRNA splicing appeared to be altered between normal and
tumour tissues, since comparison between the levels of these
genes is extremely difﬁcult. Overall, our study seems compar-
able with the three other most similar studies in the ﬁeld
(1,4,5) in that there was considerable, but incomplete,
overlap for a core set of 20–30 genes that are generally
accepted as differentially expressed under Wnt-ON and
Wnt-OFF conditions. Many other real targets were probably
present in our list, the stringency of our ﬁltering being
reﬂected in the fact that only 37 of our 215 differentially
expressed genes were not detected by any of the other three
studies. This assertion was conﬁrmed by our pooled analysis
with the Sabates-Bellver data (4), in which ,25% of the
genes in our 60 þ 151 ‘gene signature’ genes were rendered
absent from the combined data using a ﬁlter of FDR , 0.001.
In summary, the identiﬁcation of genes with expression
changes in early colorectal adenomas helps to identify the
mechanisms of colorectal tumorigenesis and to provide poten-
tial targets for prevention and therapy. It is essential that a
multi-stage approach is taken to this work, both for validation
and so that different strands of evidence can be incorporated,
including expression proﬁling and the discovery of TCF4/
beta-catenin-binding sites. In this study, we have reported
our own expression proﬁling data and some new early and
consistent changes in human and mouse intestinal adenomas.
We have also undertaken comparative and pooled analyses
that between them have enabled us to propose new direct or
indirect Wnt targets with some conﬁdence. Several of the
newly identiﬁed, differentially expressed genes represent
potential diagnostic or therapeutic targets for intestinal
tumours.
MATERIALS AND METHODS
Microarray expression analysis
Initially, three ‘classical’ FAP patients carrying germline
mutations (Q163X, S1190X and delATnt2396) in the APC
gene were identiﬁed. Sixteen snap-frozen adenomas (all with
previously characterized somatic APC mutations) were col-
lected from these patients; all lesions were mildly dysplastic
adenomas of ,0.5 cm diameter derived from different sites
within the large bowel. Eight snap-frozen samples of normal
bowel were collected from the same three patients and two
additional FAP cases. mRNA was extracted from each
sample with the GenElute mammalian total RNA miniprep
kit (Sigma, RTN70) All subsequent steps in the microarray
expression analysis were carried out by the Cancer Research
UK GeneChip Microarray Service. Brieﬂy, after quality
control, the RNAs were reverse-transcribed to double stranded
complementary DNA (cDNAs) and biotin-labelled comp-
lementary RNA (cRNA) was ampliﬁed by in vitro transcrip-
tion with T7 RNA polymerase. cRNAs were then hybridized
to HGU133A Affymetrix Chips. Full protocols are available
at http://bioinformatics.picr.man.ac.uk/mbcf/protocols.jsp
For Apc
Min/þ (Min) mice, three series of small- or large-
bowel adenomas and normal intestinal epithelium were
studied. All samples were removed at autopsy and snap-
frozen. For series 1, mRNA was extracted and cRNA prepared
from 24 small-bowel adenomas and 24 normal samples from
six mice as described earlier; samples from each mouse
were pooled, before hybridization to 12 Affymetrix
MOE430_2 arrays using the manufacturer’s protocols. For
series 2, tissue was homogenized using the FastRNA Kit
(Q-Biogene) and total RNA prepared using the RNEasy kit
(Qiagen). RNAs from up to ﬁve tumours or normal epithelium
from eight individual mice were pooled before hybridization
to the Affymetrix MG_U74Av2 arrays using the manufac-
turer’s protocols; this resulted in the following pools being
analysed – two tumours and two normal from the large
bowel, and four tumours and two normal from the small
bowel. For series 3, samples were prepared as for series 1;
RNAs from nine small bowel adenomas and from six
normal epithelial samples were each hybridized to Affymetrix
MOE430_2 arrays.
Quantitative reverse transcription polymerase
chain reaction
In order to provide further evidence of the changes identiﬁed
by expression microarrays, mRNA was extracted from snap-
frozen human FAP samples (on average, eight normal
samples, 10 adenoma samples and four colorectal carcinoma
samples were investigated for each gene) and Apc
Min/þ
mouse samples (on average, 32 normal and 29 tumour
samples) with GenElute mammalian total RNA miniprep kit
(Sigma, RTN70) and converted to cDNA with First Strand
cDNA synthesis kit (Amersham biosciences) according to
the manufacturer’s protocol. cDNAs were puriﬁed using the
QIAquick PCR puriﬁcation kit (Qiagen, 28104) and 30 ng of
cDNA were used for each reaction. TaqMan Gene Expression
Assays (Applied Biosystems) were used for each gene of inter-
est. Details are available from the authors on request. Absolute
quantiﬁcation qRT–PCR was performed on the ABI 7900HT
(Applied Biosystems) according to the manufacturer’s instruc-
tions and data were analysed with the comparative Ct method
(with GAPDH serving as endogenous Control) as described in
Applied Biosystems’s User Bulletin No. 2.
For analysis of target mRNA expression in RKO, cells were
seeded and left to grow to 80% conﬂuence. The cells were
then treated with the protein synthesis inhibitor cycloheximide
(60 ug/ml, Sigma) for 2 h, before addition of 20 mM LiCl (test)
or KCl (Control). No-treatment and cycloheximide-only
samples were also analysed. The cells were incubated for
24 h and RNAs were then extracted from pelleted cells
using the GenElute total mammalian RNA kit (RTN-70,
Sigma). RNAs were reverse transcribed into cDNA using the
AfﬁnityScriptTM QPCR cDNA Synthesis Kit (Stratagene),
according to the manufacturer’s protocol. cDNAs were puri-
ﬁed using the QIAquick PCR puriﬁcation kit (QIAGEN) and
used (30 ng per reaction) to assess expression of the putative
Wnt target genes CXCL3, ETS2, GNA11, GREM1, GREM2,
ITGA6, LGR5, PHLDA1, RARRES2, SEMA3F, SGK1 and
TACSTD2 with TaqMan Gene Expression Assays (details
available on request), according to manufacturer’s protocol.
Each sample was run in duplicate and the data obtained
were analysed using the comparative Ct method (as described
in Applied Biosystems User Bulletin No. 2), using GAPDH as
an endogenous Control and comparing LiCl- with KCl-treated
Human Molecular Genetics, 2008, Vol. 17, No. 24 3873cells. The fold change in mRNA expression levels was calcu-
lated as 2
2ddCt.
In situ hybridization
Isotopic ISH was performed essentially as previously described
(24) on the following genes: MYC, EPHB2, MMP7, CD44,
GPR49/LGR5, SGK1, GNA11, ETS2, GREM2, ITGA6 and
RARRES2. Brieﬂy, templates for riboprobe synthesis were gen-
erated by amplifying from cDNA PCR products of 500 bp,
spanning exon–exon boundaries, and cloning them into the
vector pGEM3Z. All templates were sequenced prior to ribop-
robe synthesis. Details of primers used and correspondence
between ISH probes and TaqMan Gene Expression Assays
are shown in Supplementary Material, Table S3. Riboprobes
were generated by in vitro transcription using the RNA poly-
merase Sp6 and hybridized to 4 mm sections, cut from eight
formalin-ﬁxed, parafﬁn-embedded specimens. A beta-actin
probe was generated and used as a hybridization control.
Data analysis
Raw gene expression data were imported into the GeneSpring
program and the Mas5 algorithm was used to average across
the different probes per gene present in each array. Data for
each chip were normalized by median-centering (i.e. to the
median of all values on a given array). Data were included
if a probeset was present in at least one sample probe set
per data series. Differential expression was deﬁned as exceed-
ing a speciﬁed fold change in either direction with a speciﬁed
degree of conﬁdence; in general, higher fold-changes and
lower P-values or FDRs were speciﬁed for the initial screens
than for the veriﬁcation experiments. For meta-analysis of
our own data and those of others, signal intensity estimates
for the extra data sets were Mas5 generated and the data
median centred as for our own human data set. Since both
data sets were from Affymetrix arrays, probesets with identi-
cal IDs were identiﬁed and analysed. Tumour and experiment
effect variance was modelled using ANOVA. Differential
probe sets between the adenoma and normal cases were
identiﬁed using a 0.001 FDR correcting for any experiment
effect across the samples. The analysis was carried out using
the Limma and Affy packages from Bioconductor 2.2 within
R 2.7.0.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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